Company intelligence / Profile preview

Bloom Therapeutics

San Diego, United Statesbloomtherapeuticsllc.com ↗

Ownership: Private
Development stage: Other

Overview

BL-001 demonstrated safety/tolerability in healthy volunteers with statistically significant weight loss observed at day 28. Preclinical data show anticonvulsive efficacy in mouse models of epilepsy. Plans underway for Phase 2 trials in Dravet syndrome and ALS.

Therapeutic areas: Metabolic DisordersNeurology
Modalities: Live biotherapeutic product therapy (LBP)Microbial therapySynthetic biology-based engineered bacteria
Industry: Biotech

Beyond the preview

Go deeper on Bloom Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bloom Therapeutics.

Explore the full profile